July 16, 2023 – For months, it has been considered the slimming miracle elixir: the pharmac0logically active ingredient Semaglutide. Semaglutide is a GLP-1 receptor agonist, which means it mimics the action of human incretin glucagon-like peptide-1 (GLP-1). This improves insulin …

Is Semaglutide a weight loss miracle? Read more »

March 10, 2022 – In a new report distributed in “Circulation: Genomic and Precision”, scientists showed that as while numerous African Americans, particularly those with a high African Family extent, have a good lipid profile, they are at a higher …

Genetic variations and social health determinants may lead to higher risk for diabetes in individuals with high African heritage Read more »

February 20, 2020 – Traditional cardiovascular risk factors often assessed in an annual physical, such as blood pressure, cholesterol levels, diabetes, and smoking status, may at least be as valuable in predicting who will develop coronary heart disease (CHD) as …

Heart disease prediction by traditional risk factors as good as with an exhaustive genetic test Read more »

December 20, 2018 – This is very troubling news for all patients worldwide with diabetes and who are under therapy with drugs out of the DPP-4 class of inhibitors:  A very recent population-based epidemiological study indicates that patients under DPP-4 inhibitors …

Cholangiocarcinoma: Diabetes Drugs In DPP-4 Inhibitor Class Associated With Doubled Risk Read more »

May 06, 2018 – In April 2016 the American Food and Drug Administration (FDA) took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for  new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) …

Heart attacks and stroke: The risk of DPP-4 anti-diabetes drugs Read more »

November 14, 2017 – Diabetes is manageable if you know how Article by author Chloe Pearson. Article top photo Jenny Hill at Unplash. If you have diabetes, you already know that staying healthy is going to be a challenge: Keeping track …

Diabetes is manageable if you know how Read more »

October 15, 2017 – According to the quarterly safety report April – June 2017 by the American Food & Drug Administration (FDA), originating from the  FDA Adverse Event Reporting System (FAERS), the class of diabetes drugs referred to as dipeptidyl peptidase-4 …

Diabetes: Is rhabdomyolysis associated with DPP-IV inhibitors? Read more »

April o5, 2016 – There have been indications that a heightened risk of heart failure may be associated with diabetes medications containing the pharmacologically active ingredients saxagliptin or alogliptin.  In the US, this includes  the FDA-approved drugs Saxagliptin (Onglyza), Saxagliptin/Metformin …

Is there a heightened risk of heart failure with diabetes medications containing saxagliptin and alogliptin? Read more »

23. September 2010 – Das Arzneimittel-Institut der Schweiz (Swissmedic) hat heute folgende Mitteilung veröffentlicht: 23.9.10. – Swissmedic.  Die Arzneimittelbehörde der EU (EMEA) sieht vor, die Zulassung der Diabetes-Medikamente mit dem Wirkstoff Rosiglitazon zu suspendieren; sie werden dort in einigen Monaten …

Diabetes-Arzneimittel mit dem Wirkstoff Rosiglitazon – Vorgesehene Sistierung der Zulassung in der Europäischen Union. Read more »